Neutrophil Lymphocyte Ratio and Transarterial Chemoembolization in Neuroendocrine Tumor Metastases

McDermott, Sean M.; Saunders, Neil; Schneider, Eric B.; Strosberg, David S.; Onesti, Jill K.; Dillhoff, Mary; Schmidt, Carl; Shirley, Lawrence A.

doi:10.1016/j.jss.2018.06.058

Cited by 11 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although surgery combined with radiotherapy and chemotherapy has been widely used, prolonging the survival of patients with SSCC remains a challenge. Many studies have found that systemic inflammatory response is closely related to the prognosis of patients with various tumors including SSCC, which provides a new basis for the stratified treatment of patients 13,14…”

Section: Discussionmentioning

confidence: 99%

<p>Prognostic Value Of The Preoperative Neutrophil To Lymphocyte Ratio In Patients With Sinonasal Squamous Cell Carcinoma</p>

Zhong¹,

Deng²,

Du³

et al. 2019

CMAR

View full text Add to dashboard Cite

Objective: This study explored the effectiveness of a new inflammatory prognostic system, using preoperative neutrophil to lymphocyte ratio (NLR) to predict the postoperative survival rate of patients with sinonasal squamous cell carcinoma (SSCC). Methods: Patients diagnosed with SSCC who undergone surgically treated without neoadjuvant therapy were included in the study between May 2008 and October 2017. Preoperative NLR is defined as: preoperative neutrophil/postoperative lymphocyte ratio. The prognostic value was uncovered by univariate and multivariate Cox hazards analysis. Results: A total of 147 patients were included in this study. Through the multivariate analysis, pathological T stage (hazard ratio [HR] 1.719, confidence interval [CI] 1.277-3.642, p<0.001), pathological N stage (HR 1.344, 95% CI 1.015-2.776, p<0.001), and preoperative NLR (HR 1.579, 95% CI 1.217-3.092, p=0.002) were independent risk factor for overall survival (OS). Pathological T stage (HR 1.835, 95% CI 1.141-3.132, <0.001), pathological N stage (HR 1.281, 95% CI 1.169-2.476, p<0.001), and preoperative NLR (HR 1.688, 95% CI 1.162-3.363, p p<0.001) were also independently associated with disease-free survival (DFS). Pathological T stage (HR p<0.001, 95% CI 1.537-3.021, p<0.001), pathological N stage (HR1.571, 95% CI 1.157-2.258, p<0.001), and preoperative NLR (HR 1.509, 95% CI 1.153-3.104, p=0.001) were independent risk factors for disease-specific survival (DSS). Conclusion: The preoperative NLR is considered to be a useful predictor of postoperative survival in SSCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Prognostic Value Of The Preoperative Neutrophil To Lymphocyte Ratio In Patients With Sinonasal Squamous Cell Carcinoma</p>

Zhong¹,

Deng²,

Du³

et al. 2019

CMAR

View full text Add to dashboard Cite

show abstract

“…Other series supported an elevated NLR as an independent predictor of metastasis in NET patients, although different cut-offs have been proposed (2.2 in gastric NETs ( 73 ); 2.63 in midgut NETs ( 70 ); 1.8-3.71 in pancreatic NETs ( 75 , 77 , 78 , 81 )). The prognostic value of NLR has also been confirmed in a series of 262 patients with metastatic NETs undergoing transarterial chemoembolization, where serum NLR before and 6 months after intervention independently predicted survival, suggesting a role for NLR in decision-making and assessing treatment responses ( 33 ).…”

Section: Neuroendocrine Tumorsmentioning

confidence: 91%

“…NETs are neoplasms originating from the epithelium of organs with neuroendocrine differentiation that typically have not only an indolent behavior but also metastatic potential ( 33 ). An increased inflammatory status has known effects in tumorigenesis and tumor progression, locally ( 104-107 ) and systemically ( 35 , 69 , 83 , 108 , 109 ).…”

Section: Neuroendocrine Tumorsmentioning

confidence: 99%

Serum Inflammation-based Scores in Endocrine Tumors

Marques

Vries

Dekkers

et al. 2021

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context Serum inflammation-based scores reflect systemic inflammatory response and/or patients’ nutritional status, and may predict clinical outcomes in cancer. While these are well-described and increasingly used in different cancers, their clinical usefulness in the management of patients with endocrine tumors is less known. Evidence acquisition A comprehensive PubMed search was performed using the terms “endocrine tumor”, “inflammation”, “serum inflammation-based score”, “inflammatory-based score”, “inflammatory response-related scoring”, “systemic inflammatory response markers”, “Neutrophil-to-lymphocyte ratio”, “Neutrophil-to-platelet ratio”, “Lymphocyte-to-monocyte ratio”, “Glasgow Prognostic Score”, “Neutrophil-Platelet Score”, “Systemic Immune-Inflammation Index”, and “Prognostic Nutrition Index” in clinical studies. Evidence synthesis The Neutrophil-to-Lymphocyte Ratio and the Platelet-to-Lymphocyte Ratio are the ones most extensively investigated in patients with endocrine tumors. Other scores have also been considered in some studies. Several studies focused in finding whether serum inflammatory biomarkers may stratify the endocrine tumor patients’ risk and detect those at risk for developing more aggressive and/or refractory disease, particularly after endocrine surgery. Conclusions In this review, we summarize the current knowledge on the different serum inflammation-based scores and their usefulness in predicting the phenotype, clinical aggressiveness, disease outcomes and prognosis in patients with endocrine tumors. The value of such serum inflammation-based scores in the management of patients with endocrine tumors has been emerging over the last decade. However, further research is necessary to establish useful markers and their cut-offs for routine clinical practice for individual diseases.

show abstract

“…Increased chromogranin A and pancreastatin (a split product of chromogranin A) values; markers of hepatocyte dysfunction, including increased alkaline phosphatase and elevated prothrombin time; evidence of malnutrition as demonstrated by low serum albumin; and neutrophil:lymphocyte ratio >4 have all correlated with worse outcomes after embolization. 108,[114][115][116]133,134 Imaging markers have also demonstrated prognostic value. Luo et al evaluated pre-TACE multiparametric MRI and found tumor volume of the dominant lesion and volumetric enhancement values during the arterial and venous phases of imaging to be prognostic of both HPFS and OS.…”

Section: Conventional Tace For Net Liver Metastasesmentioning

confidence: 99%

Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?

DePietro,

Li,

Shamimi-Noori

2024

Semin intervent Radiol

View full text Add to dashboard Cite

Liver metastases are the most common malignancy found in the liver and are 20 to 40 times more common than primary hepatic tumors, including hepatocellular carcinoma. Patients with liver metastases often present with advanced disease and are not eligible for curative-intent surgery or ablative techniques. The unique hepatic arterial blood supply of liver metastases allows interventional radiologists to target these tumors with transarterial therapies. Transarterial chemoembolization (TACE) has been studied in the treatment of liver metastases originating from a variety of primary malignancies and has demonstrated benefits in terms of hepatic progression-free survival, overall survival, and symptomatic relief, among other benefits. Depending on the primary tumor from which they originate, liver metastases may have different indications for TACE, may utilize different TACE regimens and techniques, and may result in different post-procedural outcomes. This review offers an overview of TACE techniques and specific considerations in the treatment of liver metastases, provides an in-depth review of TACE in the treatment of liver metastases originating from colorectal cancer, neuroendocrine tumor, and uveal melanoma, which represent some of the many tumors beyond hepatocellular carcinoma that can be treated by TACE, and summarizes data regarding when one should consider TACE in their treatment algorithms.

show abstract

Neutrophil Lymphocyte Ratio and Transarterial Chemoembolization in Neuroendocrine Tumor Metastases

Cited by 11 publications

References 42 publications

<p>Prognostic Value Of The Preoperative Neutrophil To Lymphocyte Ratio In Patients With Sinonasal Squamous Cell Carcinoma</p>

<p>Prognostic Value Of The Preoperative Neutrophil To Lymphocyte Ratio In Patients With Sinonasal Squamous Cell Carcinoma</p>

Serum Inflammation-based Scores in Endocrine Tumors

Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?

Contact Info

Product

Resources

About